Trial Profile
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR'S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE AGGRESSIVE NON-HODGKIN LYMPHOMA WHO ARE NOT CANDIDATES FOR INTENSIVE HIGH-DOSE CHEMOTHERAPY
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Bendamustine; Gemcitabine; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms INO-VATE
- Sponsors Pfizer
- 05 Oct 2021 This trial has been completed in Spain (End Date: 28 Mar 2014), according to European Clinical Trials Database record.
- 17 Jun 2018 Results comparing efficacy of Blinatumomab versus Inotuzumab Ozogamicin by taking patient data from TOWER and INO-VATE studies, presented at the 23rd Congress of the European Haematology Association
- 04 Aug 2017 Brazil, Greece, Hong Kong, Netherlands, Poland, Portugal, Puerto Rico, Slovakia, Switzerland and Turkey were planned locations of this trial, as reported in the European Clinical Trials Database record